Cancer Risk in Marfan Syndrome: A Swedish Population‐Based Cohort Study
International Journal of Cancer · 2026
DOI: 10.1002/ijc.70541 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Ida Nordgren und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Marfan Syndrome, Neoplasms. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research Funds of Radiumhemmet, Cancerfonden, Region Stockholm.
Abstract (Originalsprache)
Marfan syndrome is an autosomal dominant connective tissue disorder caused by pathogenic variants in the fibrillin‐1‐encoding gene. The cancer risk in Marfan syndrome is not fully understood, but recent reports have suggested an increased risk in adults. This study assessed cancer risk in Marfan syndrome using population‐based data from the Swedish National registers. We performed a register‐based nationwide matched cohort study of 1544 individuals with Marfan syndrome, born 1930–2017. Each individual was matched to 50 comparisons by birth year, sex and birth county. Cancer risk was estimated using Cox proportional hazard models, expressed as hazard ratios (HRs) with 95% confidence intervals (CIs). All cancer cases diagnosed before age 20 years were classified as childhood cancer, and those diagnosed at age 20 years or older were classified as adult cancer. The overall risk of adult cancer was not increased in individuals with Marfan syndrome (HR 1.00, 95% CI 0.78–1.27). However, there was an increased risk of endocrine tumours in adults with Marfan syndrome (HR 2.86, 95% CI 1.40–5.85). Furthermore, an over two‐fold increased risk of cancer was observed among children with Marfan syndrome (HR 2.44, 95% CI 1.25–4.80). In this study, we found an increased cancer risk in children with Marfan syndrome. In contrast to previous reports, we did not detect an increased overall cancer risk in adults with Marfan syndrome, but an elevated site‐specific risk of endocrine tumours. Further, larger studies are warranted to evaluate the lifetime cancer risk in Marfan syndrome at different ages.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
- Department of Radiology, Karolinska University Hospital, Stockholm, Sweden.
- Department of Population Health and Disease Prevention & Department of Epidemiology and Biostatistics, Joe. C. Wen School of Population Health & Public Health, University of California Irvine, Irvine, California, USA.
- Department of Clinical Genetics and Genomics, Karolinska University Laboratory, Karolinska University Hospital, Stockholm, Sweden.
- Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
ORCID-Profile: Ida Nordgren, Giorgio Tettamanti
Förderung
- Cancer Research Funds of Radiumhemmet
- Cancerfonden
- Region Stockholm
- Barncancerfonden
- Vetenskapsrådet
- Stiftelsen Promobilia
- Stiftelsen Barnavård
- H.K.H. Kronprinsessan Lovisas Förening för Barnasjukvård
Zitieren
APA
Nordgren, I., Nordenvall, A. S., Wachtmeister, A., Taylan, F., Lu, Y., Norrby, C., Lindstrand, A., Grigelioniene, G., & Tettamanti, G. (2026). Cancer Risk in Marfan Syndrome: A Swedish Population‐Based Cohort Study. International Journal of Cancer. https://doi.org/10.1002/ijc.70541
Vancouver
Nordgren I, Nordenvall AS, Wachtmeister A, Taylan F, Lu Y, Norrby C, et al. Cancer Risk in Marfan Syndrome: A Swedish Population‐Based Cohort Study. International Journal of Cancer. 2026. doi:10.1002/ijc.70541
BibTeX
@article{Nordgren2026,
author = {Nordgren, Ida and Nordenvall, Anna Skarin and Wachtmeister, Alexandra and Taylan, Fulya and Lu, Yunxia and Norrby, Christina and Lindstrand, Anna and Grigelioniene, Giedre and Tettamanti, Giorgio},
title = {Cancer Risk in Marfan Syndrome: A Swedish Population‐Based Cohort Study},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70541}
}
EUVIMED